Pricing

Nymox Pharmaceutical Corp (NYMXF)

followers ·
Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
CEO:
Paul Averback
Employees:
3
9900 CAVENDISH BLVD., SUITE 306, ST. LAURENT, QUEBEC CANADA, A8, H4M 2V2
1-800-936-9669
Nymox Pharmaceutical Corporation engages in the research and development of drugs for the aging population in Canada, the United States, Europe, and internationally. Its lead drug candidate is Fexapotide Triflutate (NX-1207), which has completed Phase III clinical trials for the treatment of benign prostatic hyperplasia. The company also develops and markets NicAlert and TobacAlert tests that use urine or saliva to detect use of tobacco products.
All 13F Filers Prior Change Hedge Funds 1 Prior Change
InvestorHistoryShares Held or Principal AmtMarket Value% of PortfolioPrevious % of PortfolioRankChange in Shares% OwnershipQtr 1st OwnedEst. Avg PriceSourceSource DateDate Reported
No data available